Focus on science. Stop guessing clinical outcomes.
Flaskdata.io is a data-driven platform for early stage drug and device clinical trials.
Flaskdata.io provides you with a same day picture of missing outcome data and adverse event trends. You execute innovative projects now. You take risk-decisions now, not 6 weeks from now.
We believe that if you develop cutting-edge therapeutics, you deserve cutting-edge data management technology at a fair price.
We work with big, publicly-traded companies and 3 man medical device startups. Thousands of patients around the world use the Flaskdata.io clinical data platform in the US, Israel, India and Brazil.
Flaskdata creates a single source of truth from API calls, mobile, cloud, wearables, medical IoT, patient ePRO and EDC from research sites. You can start small with a mobile ePRO solution for 10 patients and grow all the way to Phase 3, FDA approval and Post-marketing.
We will stand by you in good and bad times with fanatic service, straight-talk and the highest professional and ethical standards.
A secure cloud platform for your clinical data
Flaskdata was designed for security and privacy and complies with HIPAA, CCPA, GDPR, 21 CFR Part 11 and Israeli Privacy Regulations.
We specialize in early stage drug and device projects
Early stage drug and device projects are often challenged by tight budgets and an inadequate Phase 1 protocol design. We’ll provide you with robust digital data management tools that will enable you to work with a small head-count without compromising tight adherence to protocol requirements and careful monitoring of patient safety.
Our customer support and software engineering teams love to work with startups on tight budgets and challenging delivery schedules.
We provide creative, agile solutions for biopharma, connected drugs, connected medical devices, digital therapeutics and AI-driven medical applications that need to be validated for FDA approval. We love challenges.
Automate data quality and safety monitoring
Flaskdata enables you to collect data from your sites, patients and connected devices. You can define data quality and safety monitoring metrics on your patient timelines from any of the data you collect. The unified database will provide you a precise and immediate picture of missing outcome data and adverse event trends with with real-time alerts to patients, clinops teams and project managers.
The Flaskdata subscription: Zero-admin. Unlimited studies, sites, users and data.
- CTMS to manage your study portfolio
- DDC – Direct data collection
- 21 CFR compliant EDC
- Self-service Visual Forms designer
- ePRO – Desktop and native Android mobile
- Data quality and patient safety metrics
- Report tools
- External API integration
- Connected device support
- Single sign-on with Google, SAML and OPENID standards.
- The entire platform exposed as a REST API
All this for $50/month/patient in an annual subscription.
Flaskdata.io customers are successfully executing global multi-center studies in NASH, chronic constipation, AI-driven endoscopy and pre and post-marketing studies of diagnostic devices for Calprotectin, H. pylori, Campylobacter, Rotavirus and E. coli.
A pivotal study for chronic constipation put the unified database to good use by automatically integrating data from connected drugs, native mobile ePRO (in Russian, English, Arabic and Hebrew) and the sponsor EDC system.
Using a small number of heuristic rules the Flaskdata.io system measures protocol compliance in real-time integrating data streams from patients, sites and drug delivery.
High productivityFlaskdata.io automation supported a 3-person clinops team in their mission of managing over 100 research sites.
Assure adherence in challenging mental health scenarios
Flaskdata.io helps the neuroscience study team assure patient adherence by providing automated data and safety monitoring tools. Flaskdata.io Detect and Act algorithms automatically detect dosing anomalies by observing dosing titration trends over time.
Alerts are pushed to the site clinops teams and to sponsor project management in order to provide a same-day response to protocol variations.
Lung cancer remains a leading cause of death from cancer globally, due to its high incidence and late-stage diagnosis. Most patients are currently diagnosed with late-stage cancer, though research has shown 5-year survival rates are up to 10 times greater when disease is detected early.
Flaskdata.io customer Nucleix has developed an ultra-sensitive liquid-biopsy technology for earlier detection of cancer. Leveraging PCR-based epigenetics, the pioneering Nucleix testing approach uses methylation-based identification for early-stage and recurring cancer detection.
Data-driven solution for oncology
Flaskdata.io provided Nucleix with an EDC platform to perform large-scale data collection of patient medical histories and biomarkers. The data-driven solution for oncology uses the Flask API to integrate clinical data with customer machine learning algorithms in order to train optimal biomarker panels.
An ultra-sensitive, proprietary platform is capable of detecting a single cancer molecule in a background of 200,000 normal molecules.
This ultra-sensitivity enables the Nucleix EpiCheck to detect cancer at its earliest stages when treatment has the greatest impact for patients.
We're proud to have had the privilege to contribute from our know-how and technology to war on lung and bladder cancer.
We put our customers first. We care deeply about your success.
We’re a diverse and interdisciplinary team with people skills and hard-core tech skills.
We put these skills to work for you.
Schedule a call